title: A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo.
abstract: BACKGROUND
  Systemic corticosteroids have been used to arrest the progression of vitiligo. However, side effects have been a constant issue.
  
  
  OBJECTIVE
  We evaluated the clinical efficacy and side effect of oral methylprednisolone (MPD) mini-pulse therapy combined with narrow-band UVB (NBUVB) for adults with non-segmental vitiligo retrospectively.
  
  
  METHODS
  32 patients with extensive and/or spreading vitiligo received 0.5 mg/kg MPD on 2 consecutive days per week with NBUVB therapy for at least 3 months.
  
  
  RESULTS
  All of the 32 patients (100%) showed progression arrest within 12 weeks. Nineteen out of 32 patients (59.4%) presented repigmentation on more than 25% of lesions. Thirteen patients (40.6%) achieved satisfactory repigmentation in more than 50% of lesions. Only 2 patients discontinued the medication due to gastrointestinal trouble.
  
  
  CONCLUSIONS
  Oral MPD mini-pulse therapy combined with NBUVB appears effective in arresting vitiligo progression and rapidly inducing repigmentation with minimal side effects.
authors.affiliation: Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Jungsoo
authors.initials: J
authors.lastname: Lee
authors.forename: Howard
authors.initials: H
authors.lastname: Chu
authors.forename: Hemin
authors.initials: H
authors.lastname: Lee
authors.forename: Miri
authors.initials: M
authors.lastname: Kim
authors.forename: Dae Suk
authors.initials: DS
authors.lastname: Kim
authors.forename: Sang Ho
authors.initials: SH
authors.lastname: Oh
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D020551:Pulse Therapy, Drug; D012189:Retrospective Studies; D014467:Ultraviolet Therapy; D014820:Vitiligo / Q000628:therapy*; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D008775:Methylprednisolone